Home
>
US Stocks
>
Reata Pharmaceuticals Inc - Class A
Reata Pharmaceuticals Inc - Class A
RETA

Reata Pharmaceuticals Inc - Class A

$96.537.42%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
98.52
Today Low/High
95.98 / 98.52
52 Week Low/High
$76.34 / $186.82
P/E ratio
-12.7939
Market Cap
$3.47B

Company Details

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata's two most advanced clinical candidates, bardoxolone and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.
Organisation
Reata Pharmaceuticals Inc - Class A
Headquaters
Plano, Texas, US
Employees
267
Industry
Health Technology
CEO
J. Warren Huff

Discover more

Frequently Asked Questions

What is Reata Pharmaceuticals Inc - Class A share price today

Can Indians buy Reata Pharmaceuticals Inc - Class A shares?

How can I buy Reata Pharmaceuticals Inc - Class A shares from India?

Can Fractional shares of Reata Pharmaceuticals Inc - Class A be purchased?

What are the documents required to start investing in Reata Pharmaceuticals Inc - Class A stocks?

We are a SEBI registered investement advisor